RAPID ALERT

DRAP ALERT No: Nº I/S/11-26-59

Spurious/Falsified Drug Product i.e. Sandostatin LAR 20mg injection (Batch # 380531) in the Market

Date:, 17th November, 2026

Target Audience:

- Field offices of DRAP and Provincial Drug Control departments.
- Healthcare Professionals
- Consumers

Problem Statement:

M/s Nouveaux Pharma Limited, Karachi has informed the availability of their product i.e. Sandostatin LAR 20mg Injection (Batch # 380531) in the market which was intended for Turkish Market. The below-mentioned product (Batch # 380531) was not supplied through legal channels into Pakistan. Following are the details:

Sr. No.	Name of product	Batch Number	Name of manufacturer	Remarks
1	**SANDOSTATIN LAR 20mg Injection** (Octreotide Acetate 20mg)	380531	**Manufacturer:** Novartis Pharmaceutical Manufacturing GmbH, Austria. **Marketing Authorization Holder:** Nouveaux Pharma Limited, C-21, S.I.T.E, Karachi.	The product with the batch # 380531 was never supplied to Pakistan by M/s Nouveaux Pharma Limited Karachi.

Risk Statement:

The use of the above-mentioned drug product may pose serious safety and quality concerns for public health including therapeutic failure, adverse health consequences, or exposure to unknown safety risks.

Action Initiated:

The Regulatory Field Force of Provincial Drug Control Departments has been asked to conduct surveillance activities throughout the supply chain to confiscate the above-mentioned drug product.

Advice for Healthcare Professionals:

DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events

or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available on this link.

Advice for Consumers:

Consumers should not use the above-mentioned product and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above-mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

Drug Regulatory Authority of Pakistan
محفوظ، موئثر اور معیاری اشیائے علاج